Jinwu Financial News | According to the disclosure of the Hong Kong Stock Exchange on November 30, Kang Shiyun submitted a listing application to the main board of the Hong Kong Stock Exchange. UBS, CCB International, and Huatai International are co-sponsors.

Baokang Shiyun is an innovation-driven clinical-stage ophthalmology biotechnology company dedicated to developing novel and differentiated therapies. Committed to internal discovery, development and commercialization of first-of-its-kind and best-in-class ophthalmic treatments to meet unmet global medical needs.

For the years ended December 31, 2021, 2022, and the six months ended June 30, 2023, Diakang Shiyun's R&D expenses were US$8.5 million, US$15.3 million and US$11.9 million respectively.